LYMPHOMA, T-CELL, PERIPHERAL
Clinical trials for LYMPHOMA, T-CELL, PERIPHERAL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL, PERIPHERAL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, PERIPHERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for rare lymphoma hits roadblock: trial ends early
Disease control TerminatedThis study tested a combination of two drugs, ixazomib and romidepsin, for people with a rare type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The trial was stopped early after enrolling only 11 participants, so the high…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
New lymphoma drug trial halted early after safety check
Disease control TerminatedThis early-stage study tested a new drug, PF-08046045, in 22 adults with several types of advanced lymphoma (cancers of the immune system). The main goal was to check safety and side effects, and to find the best dose. The study was stopped early, so results are limited.
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC